Delivering needle-free insulin using AERx® iDMS (Insulin Diabetes Management System) technology

Diabetes Technology and Therapeutics

Volumn 9, Issue SUPPL. 1, 2007, Pages

  Wollmer, Per ^a   Pieber, Thomas R ^b   Gall, Mari Anne ^c   Brunton, Stephen ^d  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b MEDICAL UNIVERSITY OF GRAZ   (Austria)

^c NOVO NORDISK A S   (Denmark)

^d AMERICAN ACADEMY OF FAMILY PHYSICIANS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN INSULIN; INSULIN ASPART;

AREA UNDER THE CURVE; ASTHMA; CONFERENCE PAPER; DIABETES MELLITUS; DRUG ABSORPTION; DRUG DELIVERY SYSTEM; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; DRY POWDER; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; INSULIN TREATMENT; LUNG FUNCTION TEST; PATIENT COMPLIANCE; PRIORITY JOURNAL; SMOKING; UPPER RESPIRATORY TRACT INFECTION;

ADMINISTRATION, INHALATION; EQUIPMENT DESIGN; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; INJECTIONS, SUBCUTANEOUS; INSULIN; NEBULIZERS AND VAPORIZERS; REPRODUCIBILITY OF RESULTS;

EID: 34250719693     PISSN: 15209156     EISSN: None     Source Type: Journal    
DOI: 10.1089/dia.2007.0206     Document Type: Conference Paper

References (25)

1. Diabetes Control and Complications Trial Group: The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993;329:977-986.
2. Epidemiology of Diabetes Interventions and Complications Group: Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002;287:2563-2569.
3. UK Prospective Diabetes Study (UKPDS) Group: Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998;352:837-853.
4. Shichiri M, Kishikawa H, Ohkubo Y, Wake N: Long-term results of the Kumamoto Study on optimal diabetes control in type 2 diabetic patients. Diabetes Care 2000;23(Suppl 2):B21-B29.
5. Owens D, Zinman B, Bolli G: Alternative routes of insulin delivery. Diabet Med 2003;20:886-898.
6. Agu RU, Ugwoke MI, Armand M, Kinget R, Verbeke N: The lung as a route for systemic delivery of therapeutic proteins and peptides. Respir Res 2001;2: 198-209.
7. Thipphawong J, Otulana B, Clauson P, Okikawa J, Far SJ: Pulmonary insulin administration using the AERx insulin diabetes system. Diabetes Technol Ther 2002; 4:499-504.
8. Farr SJ, Warren SJ, Lloyd P, Okikawa JK, Schuster JA, Rowe AM, Rubsamen RM, Taylor G: Comparison of in vitro and in vivo efficiencies of a novel unit-dose liquid aerosol generator and a pressurized metered dose inhaler. Int J Pharm 2000;198:63-70.
9. Barnett AH: Exubera inhaled insulin: a review. Int J Clin Pract 2004;58:394-401.
10. Rave KM, Nosek L, de la Pena A, Seger M, Ernest CS, Heinemann L, Batycky RP, Muchmore DB: Dose response of inhaled dry-powder insulin and dose equivalence to subcutaneous insulin lispro. Diabetes Care 2005;28:2400-2405.
11. Pfützner A, Forst T: Pulmonary insulin delivery by means of the Technosphere drug carrier mechanism. Expert Opin Drug Deliv 2005;2:1097-1106.
12. Brunner GA, Balent B, Ellmerer M, Schaupp L, Siebenhofer A, Jendle JH, Okikawa J, Pieber TR: Dose-response relation of liquid aerosol inhaled insulin in type 1 diabetic patients. Diabetologia 2001; 44:305-308.
13. Plank J, Balent B, Bock G, Wutte A, Midtgaard A, Ronn B, Pieber T: Linear dose-response relationship of inhaled human insulin using AERx insulin diabetes management system (AERX iDMS) and subcutaneous human insulin in subjects with type 1 diabetes [abstract]. Diabetes 2004;53(Suppl 2):A113.
14. Petersen AH, Plank J, Bock G, Wutte A, Haahr H, Ronn BB, Pieber T: Onset of action of inhaled insulin via the AERx® iDMS was faster than subcutaneous human regular insulin and similar to that of subcutaneous insulin aspart [abstract]. Diabetes 2005; 54(Suppl 1):A88.
15. Kapitza C, Hompesch M, Scharling B, Heise T: Intra-subject variability of inhaled insulin in type 1 diabetes: a comparison with subcutaneous insulin. Diabetes Technol Ther 2004;6:466-472.
16. Hermansen K, Ronnemaa T, Petersen AH, Bellaire S, Adamson U: Intensive therapy with inhaled insulin via the AERx insulin diabetes management system. Diabetes Care 2004;27:162-167.
17. Moses R, Lunt H, Bartley P, O'Brien R, Donnely T, Clauson P, Vesterager A, Wollmer P, Roberts A: Preprandial inhaled human insulin via the AERx® insulin Diabetes Management System (iDMS) versus subcutaneous insulin aspart in type 1 diabetes [abstract]. Diabet Med 2006;23(Suppl 4):338.
18. Himmelmann A, Jendle J, Mellen A, Petersen AH, Dahl U, Wollmer P: The impact of smoking on inhaled insulin. Diabetes Care 2003;26:677-682.
19. rd, Chu N, Kim D, An B, Reinhardt RR: Inhaled insulin using the AERx insulin diabetes management system in healthy and asthmatic subjects. Diabetes Care 2003;26:764-769.
20. McElduff A, Mather L, Kam P, Clauson P: Influence of acute upper respiratory tract infection on the absorption of inhaled insulin using the AERx insulin diabetes management system. Br J Clin Pharmacol 2005;59:546-551.
21. Marshall MO, Heding LG, Villumsen J, Akerblom HK, Baevre H, Dahlquist G, Kjaergaard JJ, Knip M, Lindgren F, Ludvigsson J: Development of insulin antibodies, metabolic control and B-cell function in newly diagnosed insulin dependent diabetic children treated with monocomponent human insulin or monocomponent porcine insulin. Diabetes Res 1988;9: 169-175.
22. Fineberg SE, Kawabata T, Finco-Kent D, Cameron L, Krasner A: Antibody response to inhaled insulin in patients with type 1 or type 2 diabetes: an analysis of initial phase II and III Exubera trials and a two-year extension trial. J Clin Endocrinol Metab 2005;90: 3287-3294.
23. Roberts A, Wilson D, McElduff A, Prins J, Simpson R, Haahr H, Rastam J, Moses R: Pharmacokinetics of inhaled human insulin via the AERx® insulin Diabetes Management System (iDMS) in subjects with type 1 diabetes, naive and non-naive to inhaled insulin [abstract]. Diabet Med 2006;23(Suppl 4):343.
24. Lindholm A, Jensen LB, Home PD, Raskin P, Boehm BO, Råstam J: Immune responses to insulin aspart and biphasic insulin aspart in people with type 1 and type 2 diabetes. Diabetes Care 2002;25:876-882.
25. Cramer JA, Okikawa J, Bellaire S, Clauson P: Compliance with inhaled insulin treatment using the AERx iDMS Insulin Diabetes Management System. Diabetes Technol Ther 2004;6:800-807.